Despite trend toward lower stroke risk with high dose
Your search for dabigatran returned 33 results
The increased number of post-marketing reports of bleeding associated with use of dabigatran seems to be an example of stimulated reporting and may not represent an increased bleeding risk.
Combining dabigatran with certain statin medications could raise the odds for major hemorrhage in patients with atrial fibrillation, according to a study published online in CMAJ, the journal of the Canadian Medical Association.
Dabigatran is associated with higher risks of major bleeding and gastrointestinal bleeding compared with warfarin, but patients taking dabigatran also have a reduced risk of intracranial bleeding compared with those taking warfarin, according to new research.
The researchers found the risk of GI bleeding was lower for apixaban versus dabigatran or rivaroxaban.
Efficacy similar to aspirin for preventing recurrent stroke after embolic stroke of undetermined source
For patients with venous thromboembolism, extended treatment with dabigatran is noninferior to warfarin.
Linked to lower risk of intracranial bleeding, but higher risk of gastrointestinal bleeding
Patients with heart valve replacements have greater rates of thromboembolic and bleeding complications after treatment with dabigatran vs. warfarin.
Increase in risk of intracranial hemorrhage, major GI bleeding in a-fib patients taking rivaroxaban